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Objective
 
To relate the repeat length of  the androgen-
receptor CAG trinucleotide to the age of  onset of  pros-
tate cancer, stage and grade of  disease.
 
Patients and methods
 
After obtaining ethical approval,
265 patients with locally confined or locally advanced/
metastatic prostate cancer were identified and evalu-
ated for age at diagnosis (
 
<
 
65 years and 
 
>
 
75 years).
DNA was extracted from peripheral blood lymphocytes
and 1
 
µ
 
g aliquots subjected to polymerase chain reac-
tion using fluorescently labelled primers. Samples were
then run on an ABI 377 gene scan analysis gel with an
internal molecular weight marker. The length of  the
CAG repeat was determined by comparing the gene
scan product size to samples where the CAG repeat
length had been quantified using direct sequencing.
The Kruskal–Wallis, Mann–Whitney and Wilcoxon
two sample tests were used to analyse the data.
 
Results
 
The mean (range) length of  the CAG repeat in the
androgen receptor was 22.2 (10–31) in the younger
and 22.5 (16–32) in the older group, and was not sta-
tistically different. There was no significant association
between the CAG repeat length and the age of  onset of
prostate cancer (
 
P
 
=
 
0.568) or with stage (
 
P
 
=
 
0.577)
and grade (
 
P
 
=
 
0.891) of  prostate cancer.
 
Conclusion
 
These results suggest that there is no correla-
tion between the androgen receptor CAG repeat length
and the age of  onset, stage and grade of  prostate cancer,
confirming recent doubts from other similar studies of
a suggested correlation between shorter androgen
receptor CAG repeat and early onset and aggressive-
ness of  prostate cancer.
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Introduction
 
Prostate cancer is the most common urological neoplasm
diagnosed in men in the USA and Western Europe [1]; 30–
40% of  men aged 
 
≈
 
50 years are estimated to have histo-
logical evidence of  cancer of  the prostate, increasing to
70–80% of  men aged 
 
≥
 
80 years [2]. Despite a high prev-
alence of  subclinical prostate cancer in young men
(50 years old) only 
 
≈
 
8% progress to clinically significant
disease requiring treatment [3]. Intriguingly, some men
obviously live with histological evidence of  prostate cancer
for many years and indeed may never manifest clinical
symptoms [4], whilst in others the disease is aggressive,
invasive and ultimately life-threatening. The significance
of  subclinical prostate cancer in men of  all ages is at
present unclear, nor it is apparent whether men with sub-
clinical disease would benefit from radical surgery to pre-
vent disease progression. If  this were the case, there is
clearly great potential for reducing death and morbidity
from prostate cancer by early intervention. At clinical
diagnosis some prostate cancers cannot be cured by sur-
gery and patients are treated with endocrine therapy; 70–
80% of  such patients respond favourably and disease pal-
liation is achieved for several months or years [5]. How-
ever, whichever method of  hormonal ablation is chosen,
all patients with advanced disease eventually relapse with
no effective second-line treatments available. For men
with newly diagnosed metastatic prostate cancer, the
median survival time is 12–18 months.
The modulation of  androgen-regulated genes repre-
sents the most important mechanism to date for promot-
ing the growth of  prostate cancers. Current hormonal
therapies are designed to prevent the activation of  andro-
gen-regulated genes by depriving the androgen receptor
(AR) of  its ligand, and through interference with the
transactivation machinery of  the receptor protein. The
prostate requires androgens for normal glandular func-
tion [6,7] and both prostate cancer growth and therapy is
critically dependent on the existence of  a functionally nor-
mal AR [8]. Clearly changes in the activity or expression
of  the AR may be important in influencing the onset and
severity of  disease in patients with prostate cancer. Two
polymorphic regions have been identified within the cod-
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ing region of  exon 1 of  the AR; both of  these regions are
trinucleotide repeats (CAG and GGC) and may influence
the activity of  the AR. There is a reported inverse linear
relation between the CAG repeat length and the AR trans-
activation function [9]. In conditions such as Kennedy’s
disease, with long CAG repeats (
 
>
 
40) the AR shows less
transactivation activity [10], resulting in patients with
low virilization and subfertility. Prostate cells with short
CAG repeats in the AR gene would therefore have greater
sensitivity to proliferative stimulation of  androgens,
resulting in better conditions for malignant growth [11].
Interestingly, the frequency distribution of  human AR
CAG repeat length in different races varies with the inci-
dence of  prostate cancer [12]. African-Americans, who
have the highest reported incidence of  prostate cancer,
more frequently have shorter CAG repeats than Cauca-
sians and Asian-Americans [12]; 
 
≈
 
75% of  Caucasians
have 19–25 CAG repeats [13]. An association between
short CAG repeats and the early onset of  prostate cancer
has been reported [14], although other studies refute any
such relationship [15]. The GGC repeat length is also
thought to influence susceptibility to prostate adenocarci-
noma (normal repeat length 8–17 [12]). Germ-line muta-
tions in the AR gene may cause variation in the length of
the CAG and GGC repeats, altering the individual’s suscep-
tibility to prostate cancer. However, somatic mutations
might alter the AR activity within the prostate cancer cells
and lead to an early escape from hormonal control or a
more aggressive disease. Proof  of  a definite relationship
between the CAG and GGC repeat lengths and prostate
cancer may help clinicians to identify such young patients
with a high risk of  aggressive prostate cancer, and thus be
able to offer them regular screening and early radical
treatment.
The aim of  this study was to investigate the correlation
between the length of  CAG repeats and the age of  onset of
prostate cancer; we also assessed the relationships
between CAG length and prostate cancer stage and grade.
 
Patients and methods
 
Patients with histopathological evidence of  prostate can-
cer were identified from prostate cancer clinics in the West
of  Scotland. In all, 265 men with prostate cancer were
recruited and, depending on their age at diagnosis, were
divided into two groups, i.e. 155 men with an ‘early diag-
nosis’ of  prostate cancer aged 
 
≤
 
65 years were compared
with 110 men with prostate cancer who were 
 
≥
 
75 years
old at the time of  diagnosis. The Gleason score was used
to grade the tumours [16]; a Gleason score of  2–4 was
taken as low grade, intermediate as 5–7 and 8–10 as high
grade. The TNM classification was used to stage the
tumours [17]. Apart from three patients who were of
Asian ethnic origin, all patients were Caucasian. Tumour
stage, grade and PSA level were recorded at the time of
diagnosis for each patient (Table 1); the PSA levels were
assessed at 3-monthly intervals during the study.
Apart from 38 patients who were being followed by
watchful waiting, all patients received some form of  treat-
ment, i.e. radical prostatectomy (42), radical radiotherapy
(47) and hormonal manipulation for advanced disease
either in the form of  LHRH analogues or antiandrogens
(126) or bilateral orchidectomy (12).
After obtaining ethical approval and patient consent, a
blood sample was withdrawn from the patients. DNA was
extracted from the peripheral blood leukocytes [18] and
stored at – 20
 
°
 
C until analysis. The AR polymorphisms
were analysed using an automated fluorescent PCR; The
5
 
′
 
 primer was fluorescently labelled for detection on an
automated DNA analyser. The primer sequence used was:
5
 
′
 
-TCCAGAATCTGTTCCAGAGCGTGC-3
 
′
 
 (forward) and
5
 
′
 
-CTTGGGGAGAACCATCCTCA-3
 
′
 
 (reverse) [19].
The PCR conditions were: 95
 
°
 
C for 5 min followed by
95
 
°
 
C for 1 min, 53
 
°
 
C for 1 min and 72
 
°
 
C for 2 min, all
repeated for 30 cycles, followed by 72
 
°
 
C for 20 min and
15
 
°
 
C for 10 min. PCR products were analysed using an
ABI 377 automated DNA analyser (Perkin Elmer Applied
Biosystems Ltd, UK) using Genescan software. The PCR
product size range was 270–310 bp. The length of  the
CAG trinucleotide repeat was determined by comparing
the product size to samples where the CAG repeat length
had previously been quantified using direct sequencing.
The Kruskal–Wallis, Mann–Whitney and Wilcoxon two
sample test were used to analyse the data.
 
Table 1
 
The number of  patients and number of  mean CAG
repeats in each stage and grade
 
Variable
Age at diagnosis 
 
<
 
65
 
≥
 
75
 
Stage
T1 71 48
T2 46 26
T3 24 23
T4 14 13
Grade
2–4 56 26
5–7 70 63
8–10 29 21
Stage
T1 22.0 22.2
T2 22.2 22.6
T3 22.0 22.7
T4 23.1 22.7
Grade
2–4 21.5 22.2
5–7 22.6 22.5
8–10 22.5 22.7
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Results
 
The mean (range) length of  the CAG repeat in the AR was
22.2 (10–31) in the younger and 22.5 (16–32) in the
older group, with an overall mean of  22.3; there was no
significant difference between the groups (
 
P
 
=
 
0.568;
Table 1). When CAG repeat lengths in patients with pros-
tate cancer diagnosed when 
 
≤
 
55 years old were compared
with those of  patients diagnosed when 
 
≥
 
75 years old,
there was again no significant difference, and none
between the CAG repeat length and the age of  onset of
prostate cancer (Fig. 1a). The mean CAG repeat length for
T1 was shorter than that for T4 tumours (Table 1), but
this was not significant (
 
P
 
=
 
0.577; Fig. 1b). Low-grade
tumours (Gleason score 2–4) had slightly shorter CAG
repeats than high-grade tumours (Gleason score 8–10),
but again this was not significant (
 
P
 
=
 
0.891; Fig. 1c).
There was no significant difference with stage or grade for
patients with short or long CAG repeats.
 
Discussion
 
The PCR technique has been used extensively with good
accuracy in molecular biology to enhance and amplify the
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Fig. 1.
 
 
 
The frequency distribution of  CAG 
repeat length in the AR among: 
 
a,
 
 the 
different age groups (open bars 
 
<
 
55 years, 
green bars, 
 
<
 
65 years; red stipple, 
 
≥
 
75 years); 
 
b,
 
 T stage (open bars, T1, green 
bars, T2; red stipple, T3; light green dashed, 
T4); and 
 
c,
 
 Gleason grade (open bars, 1–4; 
green bars, 5–7; red stipple, 8–10).
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DNA segment being studied; however, no single protocol
is appropriate to all situations. Various problems, includ-
ing low product yield, presence of  nonspecific background
bands, formation of  ‘primer-dimers’ competing for ampli-
fication, and mutations or heterogeneity caused by mis-
incorporation have been encountered. To minimize the
risk of  error, various modifications were used in optimizing
PCR conditions, sample sequencing and allele typing [20].
The AR CAG repeat length in the DNA extracted from
peripheral blood lymphocytes may be different to that
within the prostate cancer cells. If  so then the difference
may be secondary to a mutation induced within the pros-
tate cell AR by the cancer, and be a secondary event. The
length of  the prostate cancer cell AR CAG repeat will thus
have no bearing on the predisposition to prostate cancer.
As the aim of  the present study was to analyse the corre-
lation between CAG repeat length and this predisposition,
the AR CAG repeat length was analysed in the DNA
extracted from peripheral blood lymphocytes.
There was no association between the CAG repeat
length in exon 1 of  the human AR gene and the early
onset of  prostate cancer. The frequency distribution of
CAG trinucleotide repeats was similar for both early- and
late-onset prostate cancers (Fig. 1).
The association of  microsatellites in the first exon of  the
human AR gene (the CAG and GGC repeats) with prostate
cancer has been studied extensively [12,13,21–23]. Pre-
vious studies [13,14] reported an increase in the odds
ratio for prostate cancer with decreasing CAG trinucle-
otide repeat length. In the present study there was no sig-
nificant difference in CAG repeat lengths between the
younger and older groups; these results are similar to
those reported by Correa-Cerro 
 
et al.
 
 [24].
Circulating androgens stimulate the proliferation of
most prostate adenocarcinomas and androgen with-
drawal is standard therapy for most patients with
advanced disease. Eventually the disease becomes andro-
gen-independent and escapes therapeutic control,
although the duration of  response to androgen with-
drawal varies widely. This loss of  hormonal dependence is
generally caused by the development of  less differentiated
tumour clones through accumulative genetic abnormali-
ties occurring mainly during cell division [25]. Assuming
that prostate cancer cells with short CAG repeats in the
AR divide more rapidly, they would be more likely to give
rise to androgen-independent cell clones early in the
tumour progression. If  this were so an association would
be expected between short CAG repeats and high-grade
prostate adenocarcinoma; such an association was
reported by Giovanucci 
 
et al.
 
 [13] and a similar trend was
reported by Bratt 
 
et al.
 
 [14]. However, the present results
showed no such association or trend between short CAG
repeats and high grade or stage of  the tumour.
The incidence of  prostate carcinoma and the length of
the CAG repeat has been reported to vary with ethnicity
[12,13]. Men of  Asian ethnic origin have long CAG
repeats and a low risk of  prostate cancer, whereas African-
Americans reportedly have short CAG repeats and a high
risk of  prostate cancer [12,13]; Caucasians are intermedi-
ate. Correa-Cerro 
 
et al.
 
 [24] studied the French-German
population and found no relationship between the length
of  the CAG repeats and the stage or risk of  prostate cancer;
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this was contradictory to results in the USA [21–23]. Cor-
rea-Cerro 
 
et al.
 
 proposed that the mixed ethnicity of  the
American population was a cause of  the relationship
between short CAG repeats and high grade and early onset
of  prostate cancer. However, Bratt 
 
et al.
 
 [14] evaluated a
population from Southern Sweden and reported that a
short CAG repeat in the AR correlated with a lower age at
diagnosis of  sporadic and familial prostate cancer, but not
with an increased risk of  prostate cancer in general.
In the present patients from the West of  Scotland, there
was no correlation between the CAG repeat length and the
age at diagnosis, or stage and grade of  prostate cancer.
These results, like those of  Correa-Cerro 
 
et al.
 
 [24] cast
doubt on the hypothesis that CAG repeat lengths have an
influence on the susceptibility of  the AR gene for prostate
cancer. 
 
In vitro
 
 studies show that AR transcriptional activ-
ity is influenced by the CAG repeat length [26], but the sig-
nificance of  this remains unconfirmed in clinical practice.
The present study represents one of  the largest cohorts
of  patients with prostate cancer in whom CAG repeats
have been assessed; it seems that the length of  the CAG
repeat in the AR has little clinical significance in prostate
cancer.
 
References
 
1 Demers RY, Swanson GM, Weiss LK, Kan TY. Increasing inci-
dence of  cancer of  the prostate. 
 
Arch Intern Med
 
 1994; 
 
154
 
:
1211–6
2 Foster CS, Cornford P, Forsyth L, Djamgoz MBA, Ke Y. The
cellular and molecular basis of  prostate cancer. 
 
Br J Urol
 
1999; 
 
83
 
: 171–94
3 Franks LM. Latent carcinoma of  the prostate. 
 
J Pathol Bacte-
riol
 
 1954; 
 
68
 
: 603–16
4 Breslow N, Chan CW, Dhom G 
 
et al.
 
 Latent carcinoma of  the
prostate at autopsy in seven areas. 
 
Int J Cancer
 
 1977; 
 
20
 
:
680–8
5 Chisholm GD, Hedlund PO, Adolfsson J 
 
et al.
 
 The TNM system
of  1992. Comments from the TNM working group. 
 
Scand J
Urol Nephrol
 
 1994; 
 
162
 
: 107–14
6 Coffey DS. The molecular biology, endocrinology and physi-
ology of  the prostate and seminal vesicles. In Walsh PC, Retik
AB, Stamey TA, Vaughan ED Jr eds, 
 
Campbell’s Urology
 
. Phil-
adelphia: WB Saunders, 1992: 221–66
7 Bruchovsky N. Androgens and antiandrogens. In Holland JF,
Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR eds,
 
Cancer Medicine
 
. 3rd edn. Philadelphia: Lea & Febiger, 1993:
884–96
8 Kyprianou N, English HF, Isaacs JT. Programmed cell death
during regression of  PC-82 human prostate cancer following
androgen ablation. 
 
Cancer Res
 
 1990; 
 
50
 
: 3748–58
9 Chamberlain N, Driver E, Meisfeld R. The length and location
of  the CAG trinucleotide repeats in the androgen receptor N-
terminal domain affect on transactivation function. 
 
Nucl
Acid Res
 
 1994; 
 
22
 
: 3181–6
10 Mhatre AN, Trifiro MA, Kaufman M, Kazemi-Esfarjani P,
Figlewicz D, Rouleau G. Reduced transcriptional regulatory
competence of  the androgen receptor in X-linked spinal and
bulbar muscular atrophy. 
 
Nat Genet
 
 1993; 
 
5
 
: 184–8
11 Hakimi J, Rondinelli R, Schoenberg M, Banack E. Androgen
receptor gene structure and function in prostate cancer.
 
World J Urol
 
 1996; 
 
14
 
: 329–37
12 Irvine RYuM, Ross R, Coetzee G. The CAG and GGC microsat-
ellites of  the androgen receptor gene are in linkage disequi-
librium in men with prostate cancer. 
 
Cancer Res
 
 1995; 
 
55
 
:
1937–40
13 Giovanucci E, Stampfer M, Krithivas K 
 
et al.
 
 The CAG repeat
within the androgen receptor gene and its relationship to
prostate cancer. 
 
Proc Natl Acad Sci USA
 
 1997; 
 
94
 
: 3320–3
14 Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang Q-X,
Olsson H. CAG repeat length in the androgen receptor gene
is related to age at diagnosis of  prostate cancer and response
to endocrine therapy, but not to prostate cancer risk. 
 
Br J
Cancer
 
 1999; 
 
81
 
: 672–6
15 Sun S, Narod SA, Aprikian A, Ghadirian P, Labrie F. Andro-
gen receptor and familial prostate cancer. 
 
Nat Med
 
 1995; 
 
1
 
:
848–9
16 Gleeson DF, Mellinger GT. The Veterans Administration Co-
operative Urological Research Group. Prediction of  prognosis
for prostatic carcinoma by combined histological grading
and clinical staging. 
 
J Urol
 
 1974; 
 
111
 
: 58–64
17 Beahrs OH, Myers MH. 
 
American Joint Committee on Cancer.
Manual for Staging of  Cancer
 
. 2nd edn. Philadelphia: JB Lip-
pincott, 1983: 159–64
18 Nanus DM, Mentle IR, Matzer RJ, Bander NH, Albino AP.
Infrequent 
 
ras
 
 oncogene point mutations in renal cell carci-
noma. 
 
J Urol
 
 1990; 
 
143
 
: 175–8
19 Sartor O, Zheng Q. Determination of  CAG repeat length in the
androgen receptor gene using frozen serum. 
 
Urology
 
 1997;
 
49
 
: 301–4
20 Bartlett JM, Crilly A, White A, Madhok R. Modification of  the
GeneScan 2500 fluorescent dye standard for accurate prod-
uct sizing. 
 
Mol Biotechnol
 
 1999; 
 
13
 
: 185–9
21 Ingles SA, Ross RKYuMC, Irvine R, La Pera G, Haile R, Coet-
zee G. Association of  prostate cancer risk with genetic poly-
morphisms in Vit D receptor and androgen receptor. 
 
J Natl
Cancer Inst
 
 1997; 
 
89
 
: 166–70
22 Hardy DO, Scher HI, Bogenreider T 
 
et al.
 
 Androgen receptor
CAG repeat lengths in prostate cancer. correlation with age
of  onset. 
 
J Clin Endocrinol Metab
 
 1996; 
 
81
 
: 400–405
23 Stanford JL, Just JJ, Gibbs M 
 
et al.
 
 Polymorphic repeats in the
androgen receptor gene. molecular markers of  prostate can-
cer risk. 
 
Cancer Res
 
 1997; 
 
57
 
: 1194–8
24 Correa-Cerro L, Wohr G, Huassler J 
 
et al.
 
 (CAG) nCAA and
GGN repeats in the human androgen receptor gene are not
associated with prostate cancer in a French-German popula-
tion. 
 
Eur J Human Genet
 
 1999; 
 
7
 
: 357–62
25 Pinker-Shaeffer C, Partin A, Isaacs W, Coffey D, Isaacs J.
Molecular and cellular changes associated with the acquisi-
tion of  metastatic ability by prostate cancer cells. 
 
Prostate
 
1994; 
 
25
 
: 249–65
26 Kazemi-Esfarjani P, Trifiro MA, Pinsky L. Evidence for a
repressive function of  the long polyglutamine tract in the
human androgen receptor: possible pathogenetic relevance
for the (CAG) n-expanded heamopathies. 
 
Human Mol Genet
 
1995; 
 
4
 
: 523–7
 578
 
 K. MIR 
 
et al.
 
© 2002 
 
BJU International
 
 
 
90
 
, 573–578
 
Authors
 
K. Mir, BSc, FRCS, Specialist Registrar.
J. Edwards, PhD, Postdoctoral Research Assistant.
P.J. Paterson, FRCS, Consultant.
M. Hehir, FRCS(Urol), Consultant.
M.A. Underwood, MD, FRCS(Urol), Consultant.
J.M.S. Bartlett, PhD, Senior Lecturer.
Correspondence: J.M.S. Bartlett, Department of  Surgery, Glasgow
Royal Infirmary, 16 Alexandra Parade, Glasgow G31 2ER, UK.
e-mail: j.m.bartlett@clinmed.gla.ac.uk
Abbreviations: 
 
AR
 
, androgen receptor.
